Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Hormone Refractory Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Mycobacterium w vaccine × Clear all
NCT00694915 2021-08-17

STCC

Cadila Pharnmaceuticals

Phase 2 Completed
122 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00680940 2012-08-07

NSCLC

Cadila Pharnmaceuticals

Phase 2 Completed
221 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated
134 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡